Algert Global LLC purchased a new position in Organon & Co. (NYSE:OGN - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 180,400 shares of the company's stock, valued at approximately $2,686,000. Algert Global LLC owned approximately 0.07% of Organon & Co. at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. GeoWealth Management LLC purchased a new stake in Organon & Co. in the fourth quarter worth about $41,000. PARK CIRCLE Co grew its holdings in Organon & Co. by 640.7% in the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company's stock worth $60,000 after purchasing an additional 3,460 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Organon & Co. in the first quarter worth about $60,000. GAMMA Investing LLC grew its holdings in Organon & Co. by 186.9% in the first quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock worth $69,000 after purchasing an additional 3,004 shares during the period. Finally, Cary Street Partners Financial LLC purchased a new stake in Organon & Co. in the fourth quarter worth about $111,000. 77.43% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of brokerages have weighed in on OGN. Evercore ISI cut shares of Organon & Co. from an "outperform" rating to an "inline" rating in a report on Friday, May 2nd. Morgan Stanley cut their price target on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Piper Sandler cut their price target on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Organon & Co. has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.
Get Our Latest Research Report on Organon & Co.
Organon & Co. Stock Performance
Organon & Co. stock traded up $0.14 during midday trading on Friday, reaching $9.42. 3,550,502 shares of the company traded hands, compared to its average volume of 4,782,985. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of 3.50, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60. The business has a 50 day moving average of $9.68 and a two-hundred day moving average of $11.43. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $23.10. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm's revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Organon & Co.'s dividend payout ratio (DPR) is currently 2.97%.
Organon & Co. Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access